Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Revlimid is a potent immunomodulatory analogue without the teratogenic effects, which has
direct anti-tumor effects, anti-angiogenic and both anti-inflammatory and T-cell
costimulatory properties. Both preclinical and clinical data indicate its efficacy solid
tumor and multiple myeloma including advanced/refractory stages with its role in enhancing
host antitumor immunity that provided the rationale to use in patients with PTCL.